Biomarker Discovery Outsourcing Services Market Size & Share 2026-2035

Biomarker Discovery Outsourcing Services Market Size

The global biomarker discovery outsourcing services market was valued at USD 15.1 billion in 2025 and is projected to grow from USD 17.9 billion in 2026 to USD 88.7 billion by 2035, expanding at a CAGR of 19.4%, according to the latest report published by Global Market Insights Inc.

The market increased from USD 10.1 billion in 2023 to USD 12.4 billion in 2024. Rising investments in research and development (R&D) are a major driver of the biomarker discovery outsourcing services market, significantly accelerating innovation and expanding the scope of precision medicine. Pharmaceutical and biotechnology companies are increasingly allocating larger budgets to identify novel diagnostic and prognostic biomarkers as part of their drug development and disease-management strategies. This surge in R&D spending is particularly pronounced in oncology, where the demand for early detection tools and targeted therapies continues to grow, further stimulating market growth. As reported by the American Cancer Society, about 611,720 cancer deaths and 2 million new cases are expected in the U.S. in 2024, illustrating the urgent need for improved biomarker-based solutions. The rising disease burden is pushing organizations to collaborate with specialized outsourcing partners who offer advanced analytical platforms, bioinformatics expertise, and high-throughput discovery capabilities. Outsourcing not only reduces operational costs but also shortens development timelines, enabling companies to translate research insights into clinically actionable biomarkers more efficiently. As investment momentum grows, outsourcing service providers are expanding their technological capabilities, such as next-generation sequencing, proteomics, and multi-omics integration, further boosting market growth. Overall, increasing R&D investments are creating a robust pipeline of biomarker programs, reinforcing demand for specialized outsourcing services.

Additionally, the growing emphasis on personalized medicine and targeted therapies is a key driver of the biomarker discovery outsourcing services market. As healthcare systems shift toward treatments tailored to an individual’s genetic, molecular, and clinical profile, the demand for highly specific and validated biomarkers has surged. Biomarkers play a crucial role in identifying patient subgroups, predicting therapeutic response, and monitoring disease progression, making them essential for developing precision-driven drug pipelines. Pharmaceutical and biotech companies increasingly rely on outsourcing partners to accelerate biomarker discovery, given the need for advanced technologies such as genomics, proteomics, and multi-omics integration. These specialized providers offer the expertise and infrastructure required to analyze complex biological data, reduce development costs, and shorten timelines. As personalized treatment approaches continue to expand across oncology, neurology, and rare diseases, the need for robust biomarker discovery services is steadily rising, fueling market growth

Biomarker discovery outsourcing services involve contracting the entire process of biomarker discovery, from detection to validation and analysis, to specially qualified external contractors. These services enable diagnostic, biotechnology, and pharmaceutical companies to focus on their core processes while outsourcing critical aspects of their research and development processes to experts at well-equipped service-providing firms.

Biomarker Discovery Outsourcing Services Market Trends

• Advancements in high-throughput technologies such as next-generation sequencing (NGS), mass spectrometry-based proteomics, and automated screening platforms are transforming the biomarker discovery landscape. These technologies enable the rapid processing of large volumes of genetic, proteomic, and metabolomic data, significantly increasing the speed and precision of identifying potential biomarkers. With the ability to analyze thousands of samples simultaneously, high-throughput systems minimize manual effort and reduce the overall cost of biomarker research.
• Additionally, for pharmaceutical and biotechnology companies, advanced platforms are crucial for uncovering disease-specific molecular signatures that support early diagnosis, drug development, and treatment monitoring. However, implementing high-throughput systems in-house requires substantial investment in infrastructure, skilled personnel, and data analytics capabilities. This challenge drives many organizations to outsource biomarker discovery tasks to specialized service providers equipped with state-of-the-art high-throughput technologies.
• Outsourcing partners leverage these advanced tools to generate robust, reproducible, and clinically relevant biomarker data at faster turnaround times. Their expertise in multi-omics analysis, bioinformatics, and large-scale data interpretation enables more accurate biomarker validation and pathway elucidation. This enhances the efficiency of preclinical and clinical research programs, making high-throughput-enabled outsourcing an attractive option for industry players.
• As high-throughput platforms continue to evolve, offering greater sensitivity, automation, and cost-efficiency, the demand for outsourcing services is expected to grow further. These technological advancements not only improve the discovery workflow but also expand the range of detectable biomarkers, strengthening the overall biomarker pipeline and leading to the expansion of the market.

Biomarker Discovery Outsourcing Services Market Analysis

Based on type, the market is segmented into predictive biomarkers, prognostic biomarkers, safety biomarkers, surrogate endpoints, and other types. The surrogate endpoints segment held a significant share in the market, with revenue of USD 7.4 billion in 2025.

• Surrogate biomarkers significantly enhance the efficiency of clinical trials by enabling earlier assessment of treatment response and disease progression. Instead of waiting for long-term clinical outcomes, researchers can rely on these early-stage indicators to evaluate efficacy much sooner, allowing studies to be completed in a fraction of the usual time.
• In addition, the adoption of surrogate endpoints is growing rapidly, particularly in oncology and rare diseases, where both emerging regulatory authorities and the U.S. FDA increasingly use them to support accelerated approvals and market access decisions. Their ability to shorten development timelines makes surrogate markers an attractive tool for drug developers seeking faster commercialization.
• The rising reliance on surrogate endpoints is also creating substantial demand for advanced biomarker discovery outsourcing services. Pharmaceutical and biotech companies often lack the specialized infrastructure and analytical capabilities required to identify, validate, and qualify surrogate biomarkers. Outsourcing partners, equipped with high-throughput platforms and multi-omics expertise, are well-positioned to accelerate this process and ensure regulatory-ready data.
• Furthermore, as drug pipelines become more focused on personalized therapies, the importance of highly predictive surrogate markers continues to grow. Outsourcing service providers are expanding their capabilities to integrate genomics, proteomics, and AI-driven analytics, enabling deeper insights into biological pathways. This supports the development of reliable surrogate endpoints and strengthens their role in adaptive trial designs, ultimately driving the growth of the biomarker discovery outsourcing market.

Based on service, the biomarker discovery outsourcing services market is segmented into genomics biomarker services, proteomics biomarker services, bioinformatics biomarker services, and other biomarker services. The genomics biomarker services segment dominated the market with the largest revenue of USD 6.7 billion in 2025.

• The growing incidence of rare genetic disorders, neurodegenerative diseases, cardiovascular conditions, and chronic ailments such as cancer is accelerating the demand for biomarker-related services. According to the Centers for Disease Control and Prevention, heart disease remained the leading cause of death in the U.S. in 2022, accounting for roughly 702,880 deaths, or nearly one in five nationwide. Such alarming mortality figures underscore the urgent need for more advanced diagnostic and therapeutic solutions, thereby driving the expansion of the genomics-based biomarker services sector.
• In addition, increasing investments from governments and private organizations are further strengthening the biomarker discovery landscape. Large-scale initiatives enable extensive genomic data collection, fostering accelerated discovery and validation of genomic biomarkers. These programs provide researchers and industry players with valuable datasets that support early disease detection and precision medicine development.
• The surge in genomic data generation is also motivating pharmaceutical and biotechnology companies to rely on specialized outsourcing partners. Many organizations lack the infrastructure, bioinformatics expertise, and high-throughput technologies required to analyze complex multi-omics datasets efficiently. Outsourcing providers equipped with next-generation sequencing platforms, advanced proteomics tools, and AI-driven analytics offer end-to-end solutions for biomarker identification, validation, and regulatory preparation, helping reduce R&D timelines.
• Furthermore, the shift toward personalized healthcare, particularly in oncology and rare disease therapeutics, is intensifying the need for robust genomic biomarkers. As treatment strategies become increasingly tailored to individual molecular profiles, service providers are expanding capabilities in genomics, transcriptomics, and single-cell analysis. These advancements not only enhance the depth of biomarker insights but also support more effective patient stratification and therapy optimization, ultimately contributing to the sustained growth of the biomarker service industry.

Based on the therapeutic area, the biomarker discovery outsourcing services market is segmented into oncology, cardiology, neurology, autoimmune diseases, and other therapeutic areas. The oncology segment dominated the market with the largest revenue of USD 5.6 billion in 2025.

• The global rise in cancer incidence is driving an urgent need for earlier detection methods, more precise diagnostic tools, and improved treatment options. According to the World Health Organization, around 20 million new cancer cases were reported worldwide in 2022, leading to approximately 9.7 million deaths. These escalating figures highlight the critical demand for advanced biomarker-based solutions, thereby fueling the expansion of this segment.
• Rapid advancements in technologies across metabolomics, transcriptomics, proteomics, and genomics are revolutionizing cancer biomarker identification. These sophisticated platforms allow researchers to analyze complex biological pathways with greater accuracy, significantly improving the detection of early molecular changes associated with cancer. As a result, technological innovation is playing a major role in strengthening segment growth throughout the forecast period.
• The growing adoption of multi-omics approaches is also prompting pharmaceutical companies to increasingly collaborate with specialized outsourcing partners. Many organizations lack the high-throughput infrastructure and computational expertise required to process large-scale cancer datasets. Outsourcing providers equipped with cutting-edge sequencing tools, proteomic analyzers, and AI-driven analytics offer comprehensive solutions that accelerate biomarker discovery and validation, reducing overall R&D timelines.
• Additionally, the shift toward personalized oncology, where treatment decisions are guided by a patient’s molecular profile, elevates the importance of reliable cancer biomarkers. Service providers are expanding capabilities in liquid biopsy analysis, single-cell sequencing, and immune profiling to support precision-based therapy development. These advancements are enhancing clinicians’ ability to stratify patients, predict therapeutic response, and monitor disease progression, thereby contributing to sustained growth in the cancer biomarker segment.

Based on end use, the biomarker discovery outsourcing services market is segmented into pharmaceutical companies, biotechnology companies, and other end users. The biotechnology companies segment accounted for the highest market share of 51.8%.

• Biotechnology companies are increasingly prioritizing drug discovery and development, a shift that necessitates biomarker-driven research approaches. By integrating biomarker-centric strategies, these companies can concentrate on their core competencies while delegating specialized tasks to external experts and service providers. This model allows them to streamline workflows and enhance R&D efficiency without stretching internal resources.
• In addition, building and maintaining advanced laboratories, high-end analytical instruments, and skilled in-house teams can be extremely costly. Outsourcing offers a more economical alternative, enabling biotech firms to access state-of-the-art technologies and expert guidance at significantly lower operational expenses. As a result, many biotechnology companies are increasingly relying on external consultants, which is contributing to the growth of this market segment.
• The rising complexity of drug development, especially with the growth of precision medicine and multi-omics research, is further accelerating the demand for biomarker discovery outsourcing. Specialized service providers offer capabilities in genomics, proteomics, metabolomics, and bioinformatics that many biotech companies lack internally. This access to advanced analytical ecosystems helps companies shorten development timelines and improve the accuracy of biomarker-based decision-making.
• Moreover, regulatory agencies worldwide are emphasizing the use of validated biomarkers to support clinical trial stratification, treatment monitoring, and efficacy assessment. To meet these evolving standards, biotech firms are turning to outsourcing partners with proven regulatory expertise and established quality systems. These collaborations help ensure compliance, enhance data reliability, and increase the likelihood of successful drug approvals, collectively strengthening the segment’s growth curve.

North America Biomarker Discovery Outsourcing Services Market

The North America region accounted for 47.4% of the global biomarker discovery outsourcing services industry share in 2025, driven by rising investments in research and development.

• North America held the largest share of the global biomarker discovery outsourcing market, underscoring how sustained R&D spending contributes strongly to its leadership position. The region’s growth is significantly propelled by rising investments in research and development, as pharmaceutical and biotechnology companies increasingly channel resources into biomarker-centric R&D to enhance drug discovery efficiency, improve clinical decision-making, and support precision medicine initiatives.
• Growing investment also reflects the region’s strategic need to accelerate drug development while managing cost pressures. With the increasing complexity of biomarker identification and validation, companies turn to outsourcing partners to gain access to advanced analytical platforms, specialized scientific expertise, and high-throughput capabilities, resources that are often too costly or impractical to build in-house.
• The U.S. holds a substantial share of market revenue due to its rapidly expanding biotechnology sector, strong regulatory framework, and highly developed healthcare infrastructure and technological capabilities. These factors collectively create a favorable environment for the advancement and adoption of biomarker-based research and services.
• Furthermore, the U.S. FDA has well-established procedures for overseeing the use of biomarkers in drug and diagnostic development. This regulatory strength supports rigorous biomarker validation efforts and encourages more robust research initiatives across the country, strengthening the overall ecosystem for biomarker innovation.
• In addition, the presence of numerous leading pharmaceutical, biotechnology, and research organizations in the U.S. fuels continuous investment in biomarker-driven R&D. These institutions frequently collaborate with specialized outsourcing partners to access advanced multi-omics technologies, sophisticated analytics platforms, and regulatory expertise, further driving market growth in the region.
• The country also benefits from extensive government-funded research programs and academic collaborations that prioritize precision medicine and data-driven healthcare solutions. These strategic programs enhance scientific innovation but also strengthen the demand for outsourcing services that support biomarker identification, validation, and clinical application.

Europe Biomarker Discovery Outsourcing Services Market

Europe's market accounted for USD 2.6 billion in 2025 and is anticipated to show lucrative growth over the forecast period.

• Europe’s strong emphasis on research and development is significantly boosting the biomarker discovery outsourcing market. Growing public and private sector funding is enabling deeper multi-omics research and early-stage biomarker identification.
• Additionally, EU-wide initiatives supporting precision medicine and large collaborative research programs are expanding the demand for specialized biomarker discovery services. These investments accelerate scientific innovation and reduce development timelines for biopharma companies.
• Furthermore, increasing R&D budgets and an expanding network of academic–industry partnerships allow organizations to outsource complex biomarker tasks to access advanced platforms and expert analytical capabilities.

Germany biomarker discovery outsourcing services market is projected to experience steady growth between 2026 and 2035.

• Germany’s expanding biologics sector is fueling the need for biomarker-centered research to support targeted therapies and complex biologic formulations. This growth is driving increased outsourcing demand.
• The country’s biopharmaceutical companies are investing heavily in monoclonal antibodies, cell therapies, and immunotherapies, all of which require robust biomarker discovery and validation processes.
• To enhance efficiency and access advanced technologies, German firms are collaborating with specialized outsourcing providers offering multi-omics platforms, regulatory expertise, and high-throughput analytical capabilities, strengthening market expansion.
• German firms are collaborating with specialized outsourcing providers offering multi-omics platforms, regulatory expertise, and high-throughput analytical capabilities, strengthening market expansion.

Asia Pacific Biomarker Discovery Outsourcing Services Market

The Asia-Pacific region is projected to show lucrative growth of about 8.3% during the forecast period.

• Asia Pacific’s rapidly growing biologics sector is creating strong demand for biomarker-driven research to support targeted therapies and novel drug classes. This surge is pushing companies to partner with outsourcing providers equipped with modern technologies.
• Countries such as China, India, South Korea, and Japan are investing heavily in biopharmaceutical manufacturing and innovation, driving the need for biomarker discovery services to support biologics pipelines.
• As biologics development becomes more complex, regional companies are increasingly relying on specialized outsourcing partners for genomics, proteomics, and bioinformatics expertise, which is accelerating market growth.

Japan biomarker discovery outsourcing services market is poised to witness lucrative growth between 2026 and 2035.

• Japan’s continuous increase in R&D spending, especially in genomics, oncology, and precision medicine, is driving demand for advanced biomarker discovery services. These investments are enabling deeper molecular research across academic and industrial sectors.
• Additionally, government initiatives supporting life science innovation and collaborations between universities and biopharmaceutical firms are accelerating biomarker-driven drug development. This is prompting companies to outsource specialized analytical and validation tasks.
• Japan’s focus on accelerating drug pipelines and reducing development timelines is driving companies to outsource biomarker discovery, providing access to cutting-edge platforms and expert bioinformatics capabilities, which boosts market growth.

Latin America Biomarker Discovery Outsourcing Services Market 

Brazil is experiencing significant growth in the biomarker discovery outsourcing services industry.

• Technological advancements in high-throughput sequencing, proteomics, and automated screening are strengthening Brazil’s biomarker discovery landscape. These tools enable faster and more accurate identification of disease-specific markers.
• Research institutions and biotech firms are adopting these advanced platforms, but the high cost of ownership encourages outsourcing to specialized service providers with established capabilities.
• As high-throughput technologies continue to evolve and become essential for precision medicine, demand for outsourcing services in Brazil is rising, supporting faster biomarker validation and drug development.

Middle East and Africa Biomarker Discovery Outsourcing Services Market 

Saudi Arabia is expected to witness significant growth during the forecast period.

• The rising burden of chronic conditions such as diabetes in Saudi Arabia is increasing the need for personalized medicine and biomarker‑driven diagnostic technologies. These health challenges are reinforcing the demand for early detection tools and precision‑based treatment strategies in the country.
• Increasing adoption of genomics and digital health programs across the region is also expanding opportunities for biomarker‑based research. As healthcare providers move toward more data‑driven care models, the need for specialized outsourcing partners with advanced analytical and multi‑omics expertise continues to grow.
• Moreover, the government’s focus on establishing research hubs, partnerships with global biotech companies, and modernization of laboratory infrastructure is supporting faster biomarker validation and development. These initiatives are accelerating the integration of precision medicine into Saudi Arabia’s healthcare system, thereby strengthening market expansion.

Biomarker Discovery Outsourcing Services Market Share

• The top players in the biomarker discovery outsourcing services industry include Almac Group, Crown Bioscience, Evotec, Parexel International, Frontage Laboratories, and Excelra. These players collectively accounted for an estimated 45% share of the global market in 2025.
• Leading service providers in the biomarker discovery outsourcing market are prioritizing advanced multi-omics platforms and workflow optimization to accelerate research efficiency and improve data accuracy. Companies are integrating next-generation sequencing (NGS), high-resolution mass spectrometry, automated sample-processing systems, and AI-driven analytics into their service offerings. These enhancements enable faster biomarker identification, reduce technical variability, and support high-throughput screening across genomics, proteomics, metabolomics, and transcriptomics studies.
• Market players are strengthening collaborations with pharmaceutical companies, biotechnology firms, academic research centers, and precision medicine initiatives. Such partnerships improve the deployment of cutting-edge discovery pipelines, ensure seamless data integration with drug development programs, and support co-development of disease-specific biomarker panels. These alliances are especially impactful in rapidly expanding research regions across Asia-Pacific, Latin America, and the Middle East, where investment in life sciences, clinical research, and multi-omics capabilities is rising quickly.
• With increasing complexity in biomarker qualification and regulatory expectations, outsourcing providers are intensifying their compliance with global standards. Emphasis is growing on data integrity, assay validation, reproducibility, sample-handling quality, and adherence to guidelines such as the FDA Biomarker Qualification Program and EMA scientific advice pathways. Providers are also investing in standardized workflows, certified laboratories, and robust quality-management systems to ensure regulatory-ready biomarker packages.
• Emerging regional service providers are focusing on cost-efficient biomarker discovery models and scalable laboratory infrastructure to meet the needs of value-driven healthcare markets. These companies are building expertise in essential biomarker services such as targeted sequencing, bioinformatics analysis, proteomic profiling, and custom assay development. Their affordable yet reliable solutions cater to diverse therapeutic areas, including oncology, neurology, immunology, and rare diseases.

Biomarker Discovery Outsourcing Services Market Companies

Few of the prominent players operating in the biomarker discovery outsourcing services industry include:

• Global players
  • Almac Group Limited
  • Bio‑Rad Laboratories
  • Crown Bioscience
  • Evotec
  • Frontage Labs
  • ICON
  • Parexel International Corporation
  • Sino Biological
• Regional players
  • Biomcare ApS
  • Emery Pharma
  • RayBiotech
  • REPROCELL
  • Selvita
  • Svar Life Science
• Emerging players
  • Excelra
  • Sapient Bioanalytics

• Frontage Laboratories

Frontage Laboratories reinforces its market position in the biomarker discovery outsourcing services landscape by consistently demonstrating strong analytical discipline, dependable research support, and a commitment to high-quality outcomes. The company’s structured approach to data evaluation and project coordination helps clients navigate biomarker initiatives with greater confidence. Its emphasis on precision, research integrity, and collaborative alignment enables smoother progression of discovery programs. By maintaining reliable performance and a focus on innovation, Frontage Laboratories remains a competitive partner for organizations aiming to strengthen biomarker-driven development efforts.

• Excelra

Excelra strengthens its competitive advantage in the biomarker discovery outsourcing services market by emphasizing insight-driven research, analytical precision, and disciplined data interpretation. The company’s strategic approach to supporting complex discovery programs helps pharmaceutical and biotechnology partners streamline decision-making and accelerate development timelines. With a focus on clarity, collaboration, and well-organized project structures, Excelra delivers meaningful contributions to biomarker-based initiatives.

• Evotech

Evotec maintains a strong role in the biomarker discovery outsourcing services market by integrating scientific rigor with data-focused research practices that support informed decision-making. The company’s emphasis on structured analysis, disciplined execution, and dependable project management helps partners progress biomarker initiatives more efficiently. Its continued investment in high-quality workflows and innovation strengthens confidence among global sponsors seeking reliable discovery support. With a long-standing reputation for precision, collaboration, and research excellence, Evotec remains well-positioned as a competitive contributor to advancing biomarker development across therapeutic areas.

Biomarker Discovery Outsourcing Services Industry News

• In November 2024, Frontage Laboratories and Medicover Integrated Clinical Services formed a strategic partnership aimed at expanding their global reach and strengthening support for multicultural clinical trials and laboratory services. This collaboration enhanced their combined genomic testing capabilities, enabling broader access to advanced analytics and improved trial efficiency. In the biomarker discovery outsourcing services market, the partnership bolstered both companies’ competitiveness by expanding global laboratory infrastructure, accelerating biomarker validation workflows, and improving service reliability for biopharma clients seeking comprehensive biomarker-driven research support.

The biomarker discovery outsourcing services market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Predictive biomarkers
• Prognostic biomarkers
• Safety biomarkers
• Surrogate endpoints
• Other types

Market, By Service

• Genomics biomarker services
• Proteomics biomarker services
• Bioinformatics biomarker services
• Other biomarker services

Market, By Therapeutic Area

• Oncology
• Cardiology
• Neurology
• Autoimmune diseases
• Other therapeutic areas

Market, By End Use

• Pharmaceutical companies
• Biotechnology companies
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE